RxDoctor Payments Data

Sean Verma, MD

Nephrology · Tampa, FLNPI 1396131165

Payments from drug & device makers

$16,071in general payments, 2019–2025

Across 235 payments — averaging $68.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$11K
  • AstraZeneca$1K
  • Vifor Pharma, Inc.$899
  • Amgen$859
  • Mallinckrodt Hospital Products Inc.$380
  • Otsuka America Pharmaceutical, Inc.$350
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$8,21951%
  • Travel & lodging$1,57310%
  • Food & beverage$6,20239%
  • Education$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,071 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$320,086
Medicare patients
495
Services billed
2,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol176$220,190
JardianceEmpagliflozin132$164,664
KerendiaFinerenone106$156,578
OzempicSemaglutide38$40,844
LokelmaSodium Zirconium Cyclosilicate34$39,764
EliquisApixaban35$34,563
MounjaroTirzepatide22$22,027
Potassium Citrate ErPotassium Citrate40$8,150
Nifedipine ErNifedipine219$4,197
Ezetimibe116$3,019
Bumetanide113$2,696
Valsartan104$2,594
Losartan Potassium285$2,341
Potassium Chloride80$2,141
Atorvastatin Calcium201$2,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,345$259,954210 claims
Boehringer IngelheimJardiance$156$164,664132 claims
BayerKerendia$10,783$156,578106 claims
Novo NordiskOzempic$14$40,84438 claims
ANI Pharmaceuticals, Inc.Valsartan$15$2,594104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.

Other nephrology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →